Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 13/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190312 | 0.93 | CYP3A4 (0.42) | CACNA1BNR1I2CYP3A4NR1H2NR1H3 | |
| SCHEMBL2191575 | 0.88 | CACNA1B (0.51) | CACNA1BNR1I2CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL2188044 | 0.88 | CACNA1B (0.51) | CACNA1BNR1I2CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL2196073 | 0.86 | CYP3A4 (0.46) | CACNA1BNR1I2CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL2189730 | 0.86 | CYP3A4 (0.46) | CACNA1BNR1I2CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL7920460 | 0.86 | CYP3A4 (0.46) | CACNA1BNR1I2CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL2189252 | 0.86 | CACNA1B (0.44) | CACNA1BNR1I2CYP3A4HSD11B1KDM4E | |
| SCHEMBL2191324 | 0.85 | CYP3A4 (0.45) | CACNA1BNR1I2CYP3A4HSD11B1KDM4E | |
| SCHEMBL2189267 | 0.85 | CYP3A4 (0.45) | CACNA1BNR1I2CYP3A4HSD11B1KDM4E | |
| SCHEMBL2191587 | 0.85 | CACNA1B (0.47) | CACNA1BNR1I2CYP3A4HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CACNA1B 23/4885NR1I2 765/4885CYP3A4 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.